Home » Topics » BioWorld Science

BioWorld Science
RSS

CANBERRA trial to evaluate RG-7774 in diabetic retinopathy

March 12, 2020

Corvus Pharmaceuticals discloses adenosine receptor modulators

March 12, 2020

Phase II study of MK-1454 and pembrolizumab in HNSCC initiated

March 12, 2020

Newave Pharmaceutical patents Bcl-2 inhibitors

March 12, 2020

Phase III GY004 study does not meet primary endpoint

March 12, 2020

U.S. researchers present biodegradable implant for antiretroviral contraceptive delivery

March 12, 2020

Aberrant DNA methylation predicts survival in acral melanoma

March 12, 2020

Phase I results for rectally administered microbicide gel formulated with IQP-0528

March 12, 2020

Safety and PK data presented for GS-9722

March 12, 2020

Update on clinical development of opaganib

March 12, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...
Gensci-134: a long-acting growth hormone receptor agonist fusion protein
BioWorld Science
Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone...